Clinical Trial Update: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating palbociclib plus fulvestrant in HR+ HER2-negative locally advanced or metastatic breast cancer after prior CDK4/6 inhibitor plus horm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Status: UNKNOWN